Supernus Pharmaceuticals Stock News

The attack had no significant impact on the business and did not cause any significant disruption to Company’s operations

The attack had no significant impact on the business and did not cause any significant disruption to Companys operations

Acquisition strengthens Parkinson’s disease portfolio and diversifies revenue and cash flow Acquisition strengthens Parkinson’s disease portfolio and diversifies revenue and cash flow

ROCKVILLE, Md., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) with respect to Supernus proposed acquisition of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) expired at 11:59 p.m. on November 22, 2021.

Marshall Wace North America L.P. bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 63,084 shares of the specialty pharmaceutical companys stock, valued at approximately $1,943,000. Several other institutional investors and []

ROCKVILLE, Md., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Companys management will participate in a fireside chat as part of the Piper Sandler 33 rd Annual Virtual Healthcare Conference, being held November 29 December 2, 2021. The Company will also host investor meetings on Wednesday, December 1, 2021.

If you''re a trend trader, consider that the strongest clear trend on the hourly chart exists on the 20 hour timeframe. The post Supernus Pharmaceuticals Inc (SUPN): Price Now Near $34.24; Daily Chart Shows An Uptrend on 100 Day Basis appeared first on ETF Daily News .

Market data depicted in this Oxcarbazepine Drug market report puts light on the macro-economic pointers with its principal market trends. It also shows the competition level in the market among the main organizations and profiles. Some of the chief terms

Related Stocks: DHHC , GFX , VYGG , SUPN , BKCC , DISH , INVA , GSBD , SIERU , GACQU , CENH , GIWWU , CAP , DEH , MAAC ,

Amalgamated Bank acquired a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 25,614 shares of the specialty pharmaceutical companys stock, valued at approximately $789,000. Several other hedge funds have also recently added to or reduced their stakes []

ROCKVILLE, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen

Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q3 2021 Results - Earnings Call Transcript

Supernus Pharmaceuticals (NASDAQ:SUPN) reported its Q3 earnings results on Wednesday, November 3, 2021 at 04:00 PM. Here's what investors need to know about the announcement.

ROCKVILLE, Md., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen

Supernus Pharmaceuticals Inc (NASDAQ: SUPN) recently announced that it had entered a definitive contract to acquire Adamas Pharmaceuticals (NASDAQ: ADMS). Supernus is to purchase this company a tende